New study checks if VedAryo tames IBD Flare-Ups

NCT ID NCT07273760

Completed Disease control Sponsor: AryoGen Pharmed Co. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 150 people with inflammatory bowel disease (ulcerative colitis or Crohn's disease) who were given VedAryo (vedolizumab) to see if it helps control their condition and is safe. Participants received the drug by IV at the start, after 2 weeks, after 6 weeks, and then every 8 weeks for a year. The main goal was to see how many had fewer symptoms at 52 weeks, and researchers also tracked any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Vedolizumab (VedAryo)
What this could lead to: If successful, this study could confirm that VedAryo is a safe and effective option for controlling inflammatory bowel disease symptoms.
What could go wrong: This is an observational study with no comparison group, so results are less reliable. It only follows 150 people for 52 weeks, so long-term safety and effectiveness are not fully assessed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN DISEASE (CD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease inflammatory bowel disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CROHN DISEASE (CD) INFLAMMATORY BOWEL DISEASE (IBD) ULCERATIVE COLITIS (UC)

Contacts and locations

Locations

Dr. Ali Beheshti-Namdar Clinic

Mashhad, Razavi Khorasan Province, Iran
Dr. Hamid Asadzadeh Aghdaei Clinic

Tehran, Iran
Dr. Hassan Vossoughinia Clinic

Mashhad, Razavi Khorasan Province, Iran
Dr. Mahtab Shabani Clinic

Tehran, Iran
Dr. Mohammad-Javad Kaviani Clinic

Shiraz, Fars, Iran
Dr. Naser Ebrahimi Daryani Clinic

Tehran, Iran
Gilan Gastroenterology and Hepatology Subspecialty Clinic

Rasht, Gilan Province, Iran
Imam Khomeini Hospital

Tehran, Iran
Mehr Specialty Clinic

Tehran, Iran
Professor Shahram Agah Gastroenterology, Hepatology, and Endoscopy Subspecialty Clinic

Tehran, Iran
Shariati Hospital

Tehran, Iran
Taleghani Hospital

Tehran, Iran

More trials for these conditions

Other studies related to the condition(s) this trial covers.